Table IV. Stratified relative risk of non-Hodgkin lymphoma (NHL) after first primary solid cancer according to initial radiotherapy treatment by NHL subtype.
| Radiotherapy | No Radiotherapy | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| First Primary Cancer* | Obs | SIR | Obs | SIR | RR† and 95% CI | Phomogeneity |
| All solid cancers | ||||||
| FL | 281 | 0.98 | 627 | 0.90 | 1.10 (0.95-1.27) | 0.224 |
| DLBCL | 635 | 1.15 | 1,287 | 0.96 | 1.21 (1.09-1.34) | |
| Other NHL | 826 | 1.07 | 1,934 | 1.03 | 1.09 (1.00-1.19) | |
| All standard radiotherapy treated solid cancers‡ | ||||||
| FL | 264 | 0.99 | 408 | 0.94 | 1.05 (0.9 0-1.23) | 0.497 |
| DLBCL | 559 | 1.08 | 735 | 0.88 | 1.20 (1.07-1.34) | |
| Other NHL | 722 | 1.00 | 1,048 | 0.89 | 1.14 (1.03-1.25) | |
| Oral cavity & pharynx | ||||||
| FL | 17 | 1.59 | 20 | 1.45 | 0.79 (0.37-1.69) | 0.389 |
| DLBCL | 36 | 1.83 | 30 | 1.14 | 1.29 (0.73-2.26) | |
| Other NHL | 20 | 0.70 | 42 | 1.11 | 0.59 (0.32-1.10) | |
| Larynx | ||||||
| FL | 8 | 0.82 | 7 | 2.20 | 0.35 (0.13-0.98) | >0.50 |
| DLBCL | 23 | 1.19 | 8 | 1.29 | 1.15 (0.46-2.84) | |
| Other NHL | 28 | 0.98 | 8 | 0.87 | 1.16 (0.53-2.56) | |
| Thyroid | ||||||
| FL | 14 | 2.03 | 4 | 0.37 | 4.38 (1.40-13.67) | 0.027 |
| DLBCL | 14 | 1.27 | 20 | 1.18 | 0.76 (0.37-1.57) | |
| Other NHL | 17 | 1.14 | 23 | 0.99 | 1.22 (0.63-2.34) | |
| Lung & bronchus (NSC) | ||||||
| FL | 11 | 1.17 | 21 | 0.78 | 2.08 (0.89-4.88) | >0.50 |
| DLBCL | 16 | 0.91 | 41 | 0.79 | 1.32 (0.70-2.52) | |
| Other NHL | 35 | 1.35 | 73 | 0.99 | 1.51 (0.94-2.44) | |
| Female breast | ||||||
| FL | 80 | 0.91 | 129 | 0.96 | 0.95 (0.72-1.26) | >0.50 |
| DLBCL | 120 | 0.85 | 192 | 0.85 | 1.01 (0.80-1.27) | |
| Other NHL | 155 | 0.83 | 265 | 0.87 | 0.94 (0.77-1.15) | |
| Cervix uteri | ||||||
| FL | 5 | 1.01 | 8 | 1.3 | 1.17 (0.34-4.09) | >0.50 |
| DLBCL | 14 | 1.78 | 11 | 1.28 | 1.18 (0.45-3.08) | |
| Other NHL | 11 | 1.02 | 14 | 1.19 | 0.85 (0.33-2.17) | |
| Endometrium | ||||||
| FL | 14 | 0.77 | 30 | 0.81 | 0.98 (0.51-1.90) | >0.50 |
| DLBCL | 37 | 1.17 | 55 | 0.88 | 1.28 (0.83-1.97) | |
| Other NHL | 42 | 0.99 | 59 | 0.72 | 1.36 (0.90-2.06) | |
| Prostate | ||||||
| FL | 106 | 1.03 | 152 | 0.89 | 1.18 (0.91-1.52) | >0.50 |
| DLBCL | 261 | 1.09 | 341 | 0.90 | 1.20 (1.01-1.41) | |
| Other NHL | 361 | 1.06 | 498 | 0.91 | 1.19 (1.04-1.37) | |
| Rectum & rectosigmoid junction | ||||||
| FL | 7 | 0.58 | 32 | 1.20 | 0.54 (0.19-1.55) | 0.027 |
| DLBCL | 31 | 1.33 | 35 | 0.65 | 2.39 (1.26-4.53) | |
| Other NHL | 40 | 1.22 | 63 | 0.83 | 1.14 (0.67-1.95) | |
Abbreviations: NSC, non-small cell; Obs, observed; SIR, standardized incidence rati o; RR, relative risk; CI, confidenc e interval; FL, follicular lymphoma;
DLBCL, diffuse large b-cell lymphoma; Other NHL, all other NHL subtypes combined
*
Testis results removed due to small numbers and to protect patient confidentiality.
†
Poisson regression modeling used to estimate RR of NHL following radiotherapy for first primary cancer stratified by sex, age, stage, and chemotherapy.
‡
Includes oral cavity & pharynx, rectosigmoid junction & rectum, larynx, lung & bronchus (NSC), female breast, cervix uteri, endometrial, prostate, testis, and thyroid cancers.